Cost of relapse in schizophrenia

Schizophrenia Bulletin

Volumn 21, Issue 3, 1995, Pages 419-429

  Weiden, Peter J ^a   Olfson, Mark ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b College of Physicians and Surgeons of Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; SCHIZOPHRENIA; TREATMENT OUTCOME;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; COST OF ILLNESS; COST SAVINGS; HUMAN; LENGTH OF STAY; PATIENT COMPLIANCE; PATIENT READMISSION; RECURRENCE; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPPORT, U.S. GOV'T, P.H.S.; TREATMENT REFUSAL;

EID: 0029051754     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/21.3.419     Document Type: Article

References (0)